CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. MARKET SHARE ANALYSIS/TOP PLAYER POSITIONING, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS
3.5. MARKET DYNAMICS

3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities

CHAPTER 4 SWINE HEALTH MARKET, BY DISEASE

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. AUJESZKY'S DISEASE (AD)

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. CLASSICAL SWINE FEVER (CSF)

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

4.4. ACTINOBACILLUS PLEUROPNEUMONIA

4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast

4.5. MYCOPLASMA HYOPNEUMONIAE

4.5.1. Key market trends
4.5.2. Growth factors and opportunities
4.5.3. Market size and forecast

4.6. SWINE ENTERIC CORONAVIRUS DISEASE

4.6.1. Key market trends
4.6.2. Growth factors and opportunities
4.6.3. Market size and forecast

4.7. PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME (PRRS)

4.7.1. Key market trends
4.7.2. Growth factors and opportunities
4.7.3. Market size and forecast

4.8. SALMONELLA

4.8.1. Key market trends
4.8.2. Growth factors and opportunities
4.8.3. Market size and forecast

CHAPTER 5 SWINE HEALTH MARKET, BY ROUTE OF ADMINISTRATION

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. INJECTABLE

5.2.1. Key market trends

5.3. ORAL

5.3.1. Key market trends

CHAPTER 6 SWINE HEALTH MARKET, BY REGION

6.1. OVERVIEW
6.2. NORTH AMERICA

6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast

6.2.3.1. U.S. market size and forecast
6.2.3.2. Canada market size and forecast
6.2.3.3. Mexico market size and forecast

6.2.4. North America Swine Health Market by Disease
6.2.5. North America Swine Health Market by Route of Administration 

6.3. EUROPE

6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast

6.3.3.1. Germany market size and forecast
6.3.3.2. France market size and forecast
6.3.3.3. UK market size and forecast
6.3.3.4. Spain market size and forecast
6.3.3.5. Rest of Europe market size and forecast

6.3.4. Europe Swine Health Market by Disease
6.3.5. Europe Swine Health Market by Route of Administration 

6.4. ASIA-PACIFIC

6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast

6.4.3.1. Japan market size and forecast
6.4.3.2. China market size and forecast
6.4.3.3. Australia market size and forecast
6.4.3.4. India market size and forecast
6.4.3.5. Rest of Asia-Pacific market size and forecast

6.4.4. Asia-Pacific Swine Health Market by Disease
6.4.5. Asia-Pacific Swine Health Market by Route of Administration 

6.5. LAMEA

6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast

6.5.3.1. Brazil market size and forecast
6.5.3.2. Turkey market size and forecast
6.5.3.3. Saudi Arabia market size and forecast
6.5.3.4. South Africa market size and forecast
6.5.3.5. Rest of LAMEA market size and forecast

6.5.4. LAMEA Swine Health Market by Disease
6.5.5. LAMEA Swine Health Market by Route of Administration 

CHAPTER 7 COMPANY PROFILES

7.1. NEOGEN CO

7.1.1. Operating business segments
7.1.2. Business performance
7.1.3. Key strategic moves and developments

7.2. NORBROOK GROUP

7.2.1. Operating business segments
7.2.2. Business performance
7.2.3. Key strategic moves and developments

7.3. ORION PHARMA

7.3.1. Operating business segments
7.3.2. Business performance
7.3.3. Key strategic moves and developments

7.4. PHIBRO ANIMAL HEALTH

7.4.1. Operating business segments
7.4.2. Business performance
7.4.3. Key strategic moves and developments

7.5. VETOQUINOL ANIMAL HEALTH PVT LTD

7.5.1. Operating business segments
7.5.2. Business performance
7.5.3. Key strategic moves and developments

7.6. BIO-VET

7.6.1. Operating business segments
7.6.2. Business performance
7.6.3. Key strategic moves and developments

7.7. DECHRA PHARMACEUTICALS PLC

7.7.1. Operating business segments
7.7.2. Business performance
7.7.3. Key strategic moves and developments

7.8. ECO ANIMAL HEALTH

7.8.1. Operating business segments
7.8.2. Business performance
7.8.3. Key strategic moves and developments

7.9. HUVEPHARMA SEA PRIVATE LIMITED

7.9.1. Operating business segments
7.9.2. Business performance
7.9.3. Key strategic moves and developments

7.10. INDIAN IMMUNOLOGICALS

7.10.1. Operating business segments
7.10.2. Business performance
7.10.3. Key strategic moves and developments